Macrophage membrane-coated nanoparticles control pathological inflammation and enhance survival in models of severe...

Area of Science:

• Biomedical Engineering
• Nanomedicine
• Immunology

Background:

• Severe bacterial pneumonia is a major global health threat with high mortality.
• Current treatments are limited, necessitating novel therapeutic strategies.
• Macrophage membrane-coated nanoparticles (MΦ-NPs) are engineered biomimetic constructs designed to neutralize bacterial virulence factors and host inflammatory responses.

Purpose of the Study:

• To investigate the therapeutic efficacy of MΦ-NPs in severe bacterial pneumonia.
• To assess the impact of MΦ-NPs on host inflammatory pathways and bacterial burden.

Main Methods:

• In vitro evaluation using human lung cells and neutrophils infected with bacteria.
• In vivo studies utilizing murine models of Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus pneumonia.
• Quantitative proteomics to analyze molecular pathways affected by MΦ-NP treatment.

Main Results:

• MΦ-NPs exhibited significant cytoprotective and anti-inflammatory effects in vitro without compromising neutrophil function.
• In vivo, MΦ-NP treatment led to improved survival rates, reduced bacterial load, and decreased pro-inflammatory cytokines in pneumonia models.
• Proteomic analysis revealed MΦ-NPs suppressed key inflammatory, coagulation, and fibrotic pathways linked to poor outcomes in human pneumonia and ARDS.

Conclusions:

• MΦ-NPs represent a potent host-directed therapy for severe bacterial pneumonia.
• This approach effectively mitigates detrimental inflammatory responses and improves clinical outcomes.
• MΦ-NPs hold significant potential for managing the severe inflammatory complications of bacterial pneumonia.